{"id":81221,"date":"2025-09-09T13:21:47","date_gmt":"2025-09-09T13:21:47","guid":{"rendered":"https:\/\/www.merckconnect.ca\/fr\/?post_type=mhh-sticky-footer&#038;p=81221"},"modified":"2026-01-23T19:30:51","modified_gmt":"2026-01-23T19:30:51","slug":"keytruda-lenvima-sticky","status":"publish","type":"mhh-sticky-footer","link":"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/keytruda-lenvima-sticky\/","title":{"rendered":"Keytruda Lenvima Sticky"},"content":{"rendered":"<div class=\"mhh-sticky-footer-panel mhh-sticky-footer-panel--c9d4c17221fdca9247d63ef700f80b62\">\n    <button class=\"mhh-sticky-footer-panel__expand-button\" \n            data-event-name=\"accordion_click\" \n            data-design-module=\"indication\"\n            data-design-category=\"accordion\"\n            data-design-label=\"expand\">\n                    <svg\n            xmlns=\"http:\/\/www.w3.org\/2000\/svg\"\n            fill=\"currentColor\"\n            viewBox=\"0 0 16 16\"\n            >\n            <path\n            d=\"M8 4a.5.5 0 0 1 .5.5v3h3a.5.5 0 0 1 0 1h-3v3a.5.5 0 0 1-1 0v-3h-3a.5.5 0 0 1 0-1h3v-3A.5.5 0 0 1 8 4z\"\/>\n            <\/svg>\n                <span>EXPAND<\/span>\n        <\/button>\n    <div class=\"mhh-sticky-footer-inner\">\n    \n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color has-text-color has-link-color wp-elements-e560e0f7bee0d0574244f840109f64d3 mhh-mcn-v1-paragraph--right  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a64e5438b50ce70a81453a4cb391f70b\" style=\"color:#6cc04a\"><a href=\"https:\/\/www.merck.ca\/fr\/wp-content\/uploads\/sites\/83\/2021\/04\/KEYTRUDA-PM_F.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Monographie de KEYTRUDA\u00ae<\/a><\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-white-color has-text-color  has-link-color has-object-object-font-size wp-elements-b9c8f93843b9e11e92736aec25306a42 mhh-mcn-v1-paragraph--center  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--18f4bcfdc69d8e2bcc38db065847a163\" style=\"background-color:#6cc04a\"><strong>KEYTRUDA\u00ae&nbsp;: RENSEIGNEMENTS IMPORTANTS SUR L\u2019INNOCUIT\u00c9<\/strong><\/p>\n\n    <\/div>\n<\/div>\n\n\n<div class=\"mhh-sticky-footer-expanded-panel mhh-sticky-footer-expanded-panel--f50bf3832e14000c7dbe72662d79e6cc \" dir=\"ltr\">\n    <div class=\"mhh-sticky-footer-expanded-panel__inner\">\n        <div class=\"mhh-sticky-footer-expanded-panel__close-button-wrapper\">\n            <button class=\"mhh-sticky-footer-expanded-panel__close-button\">\n                        <svg\n                xmlns=\"http:\/\/www.w3.org\/2000\/svg\"\n                fill=\"currentColor\"\n                viewBox=\"0 0 16 16\"\n            >\n                <path\n                d=\"M4.646 4.646a.5.5 0 0 1 .708 0L8 7.293l2.646-2.647a.5.5 0 0 1 .708.708L8.707 8l2.647 2.646a.5.5 0 0 1-.708.708L8 8.707l-2.646 2.647a.5.5 0 0 1-.708-.708L7.293 8 4.646 5.354a.5.5 0 0 1 0-.708z\"\/>\n            <\/svg>\n                                    <\/button>\n        <\/div>\n        <div class=\"mhh-sticky-footer-expanded-panel__body\">\n            \n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-white-color has-text-color  has-link-color has-object-object-font-size wp-elements-b9c8f93843b9e11e92736aec25306a42 mhh-mcn-v1-paragraph--center  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--18f4bcfdc69d8e2bcc38db065847a163\" style=\"background-color:#6cc04a\"><strong>KEYTRUDA\u00ae&nbsp;: RENSEIGNEMENTS IMPORTANTS SUR L\u2019INNOCUIT\u00c9<\/strong><\/p>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--c4a4eab29ed2d849c109718677b93cba mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--8bb36eba16cd86b318c26da230872fac mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--7a3be399fcefead8fa691b3834ae8c49\">KEYTRUDA\u00ae b\u00e9n\u00e9ficie d\u2019une autorisation de mise en march\u00e9&nbsp;:<\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--6c49c1b6f129a07a3238e4810a77e614 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"fr-CA\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    pour le traitement, en association avec le lenvatinib, des adultes atteints d\u2019un ad\u00e9nocarcinome r\u00e9nal \u00e0 un stade avanc\u00e9 (ne se pr\u00eatant pas \u00e0 une chirurgie curative ou \u00e0 la radioth\u00e9rapie) ou m\u00e9tastatique qui n\u2019ont jamais re\u00e7u un traitement \u00e0 action g\u00e9n\u00e9rale contre un ad\u00e9nocarcinome r\u00e9nal m\u00e9tastatique;    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    pour le traitement, en association avec le lenvatinib, des femmes adultes atteintes d\u2019un carcinome de l\u2019endom\u00e8tre \u00e0 un stade avanc\u00e9 non associ\u00e9 \u00e0 une forte instabilit\u00e9 microsatellitaire (IMS) ou \u00e0 une d\u00e9ficience du syst\u00e8me de r\u00e9paration des m\u00e9sappariements (SRM), dont la maladie a progress\u00e9 apr\u00e8s une chimioth\u00e9rapie ant\u00e9rieure \u00e0 action g\u00e9n\u00e9rale \u00e0 base de platine et qui ne sont pas candidates \u00e0 une chirurgie curative ou \u00e0 la radioth\u00e9rapie.    <\/li>\n\n<\/ul>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--504588b5721af677f5b5268c621343c2\"><strong><u><strong><u>Usage clinique<\/u><\/strong><\/u><strong> :<\/strong><\/strong>&nbsp;<\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--137f3cede3755b279a537c869f2203ec\">L\u2019innocuit\u00e9 et l\u2019efficacit\u00e9 de KEYTRUDA\u00ae n\u2019ont pas \u00e9t\u00e9 \u00e9tablies chez les enfants atteints d\u2019affections autres qu\u2019un m\u00e9lanome (de stade&nbsp;IIB, IIC ou&nbsp;III), un lymphome de Hodgkin classique (LHc) r\u00e9current ou r\u00e9fractaire, un lymphome m\u00e9diastinal primitif \u00e0 cellules&nbsp;B (LMPCB) r\u00e9current ou r\u00e9fractaire, ou des tumeurs solides non r\u00e9s\u00e9cables ou m\u00e9tastatiques associ\u00e9es \u00e0 une forte IMS ou \u00e0 une d\u00e9ficience du SRM.<br><br>Personnes \u00e2g\u00e9es (\u2265&nbsp;65&nbsp;ans)&nbsp;: aucune diff\u00e9rence globale quant \u00e0 l\u2019innocuit\u00e9 et \u00e0 l\u2019efficacit\u00e9 n\u2019a \u00e9t\u00e9 signal\u00e9e entre les patients \u00e2g\u00e9s (65&nbsp;ans et plus) et les patients plus jeunes (moins de 65&nbsp;ans) recevant KEYTRUDA\u00ae en monoth\u00e9rapie. Aucune diff\u00e9rence globale quant \u00e0 l\u2019innocuit\u00e9 et \u00e0 l\u2019efficacit\u00e9 n\u2019a \u00e9t\u00e9&nbsp;signal\u00e9e entre les patients \u00e2g\u00e9s (65&nbsp;ans et plus) et les patients plus jeunes (moins de 65&nbsp;ans) recevant le traitement d\u2019association avec KEYTRUDA\u00ae. Les donn\u00e9es quant \u00e0 l\u2019innocuit\u00e9 et l\u2019efficacit\u00e9 de KEYTRUDA\u00ae sont limit\u00e9es chez les personnes \u00e2g\u00e9es de 65&nbsp;ans et plus (n&nbsp;=&nbsp;20) atteintes d\u2019un&nbsp;LHc.<\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f279dcf193b60e355df99dd9cbefba61\"><\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-black-color has-text-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a1d943a61b3470d044a11239921cc566\"><strong><strong><span style=\"text-decoration: underline\">Mises en garde et pr\u00e9cautions pertinentes<\/span> :<\/strong><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--0d3f11a60a8ae5c5e21028e2f1cb0b1f mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"fr-CA\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Effets ind\u00e9sirables \u00e0 m\u00e9diation immunitaire, y compris des cas s\u00e9v\u00e8res et des cas mortels\u00a0:    <\/li>\n\n<\/ul>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--38557840ea3861ed76399ef47dbcdcf8 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"fr-CA\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Pneumonite    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Colite    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    H\u00e9patite    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    N\u00e9phrite et dysfonction r\u00e9nale    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Endocrinopathies, y compris l\u2019insuffisance surr\u00e9nalienne, l\u2019hypophysite, le diab\u00e8te de type\u00a01 et les troubles thyro\u00efdiens    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    R\u00e9actions cutan\u00e9es s\u00e9v\u00e8res, y compris des cas de syndrome de Stevens-Johnson et d\u2019\u00e9pidermolyse bulleuse toxique    <\/li>\n\n<\/ul>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--0a49151c136fac2748265cc17a8a672a mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"fr-CA\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Autres effets ind\u00e9sirables \u00e0 m\u00e9diation immunitaire, y compris l\u2019uv\u00e9ite, l\u2019arthrite, la myosite, l\u2019enc\u00e9phalite, la sarco\u00efdose, le syndrome myasth\u00e9nique\/myasth\u00e9nie grave, la vasculite, le syndrome de Guillain-Barr\u00e9, l\u2019an\u00e9mie h\u00e9molytique, la pancr\u00e9atite, la my\u00e9lite, l\u2019hypoparathyro\u00efdie, la gastrite, la p\u00e9ricardite, la myocardite, la cholangite scl\u00e9rosante, l\u2019an\u00e9mie aplasique et l\u2019insuffisance pancr\u00e9atique exocrine    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Rejet du greffon \u00e0 la suite d\u2019une greffe d\u2019organe plein    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Administration en association avec l\u2019axitinib pour le traitement d\u2019un ad\u00e9nocarcinome r\u00e9nal    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Allogreffe de cellules souches apr\u00e8s et avant le traitement    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    R\u00e9actions s\u00e9v\u00e8res li\u00e9es \u00e0 la perfusion    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Toxicit\u00e9 t\u00e9ratog\u00e8ne    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Les femmes qui peuvent devenir enceintes doivent utiliser une m\u00e9thode de contraception des plus efficaces et prendre des mesures pour \u00e9viter une grossesse pendant le traitement et pendant au moins quatre mois suivant l\u2019administration de la derni\u00e8re dose     <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Il faut conseiller aux femmes de ne pas allaiter pendant le traitement et pendant au moins quatre mois apr\u00e8s l\u2019administration de la derni\u00e8re dose    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Patients atteints d\u2019insuffisance h\u00e9patique    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Insuffisance r\u00e9nale    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Conduite de v\u00e9hicules et utilisation de machines    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Exigences de surveillance    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Enfants \u00a0    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Personnes \u00e2g\u00e9es    <\/li>\n\n<\/ul>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--8e091e1f06e6bd9ca8b41565d2c808d5\"><strong><span style=\"text-decoration: underline\"><strong>Pour de plus amples renseignements<\/strong><\/span><strong>&nbsp;:<\/strong><\/strong><\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f28fed0e78280d5a0d066425a7a691a5\">Consultez la <a href=\"https:\/\/www.merck.ca\/fr\/wp-content\/uploads\/sites\/83\/2021\/04\/KEYTRUDA-PM_F.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">monographie de KEYTRUDA\u00ae<\/a> pour obtenir des renseignements importants sur les effets ind\u00e9sirables, les interactions m\u00e9dicamenteuses et la posologie qui n\u2019ont pas \u00e9t\u00e9 abord\u00e9s dans le pr\u00e9sent document. Vous pouvez aussi obtenir la monographie du produit en t\u00e9l\u00e9phonant au <span class=\"no-text-breaking\">1&nbsp;800&nbsp;567-2594<\/span> ou en envoyant un courriel \u00e0 <span class=\"no-text-breaking\">medinfocanada@merck.com.<\/span><\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 dir=\"ltr\" lang=\"en-US\" class=\"wp-block-heading  has-border-color has-has-red-border-color-border-color has-white-color has-text-color  has-link-color has-object-object-font-size wp-elements-3ab1be07a887544f410a99894ded904f mhh-mcn-v1-heading--center mhh-mcn-v1-heading mhh-mcn-v1-heading--7bdcfe913b1096163b514a94a611f695\" style=\"background-color:#931d5e\"><strong>LENVIMA\u00ae&nbsp;: RENSEIGNEMENTS IMPORTANTS SUR L\u2019INNOCUIT\u00c9<\/strong><\/h3>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--681d80c5067d478d046fe84e7204ee9e\">LENVIMA\u00ae (capsules de lenvatinib) est indiqu\u00e9&nbsp;:<\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--76dab12c837fd6709ecfc44cf8772949 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"fr-CA\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    pour le traitement, en association avec le pembrolizumab, des adultes atteints d\u2019un ad\u00e9nocarcinome r\u00e9nal \u00e0 un stade avanc\u00e9 (ne se pr\u00eatant pas \u00e0 une chirurgie curative ou \u00e0 la radioth\u00e9rapie) ou m\u00e9tastatique qui n\u2019ont jamais re\u00e7u un traitement \u00e0 action g\u00e9n\u00e9rale contre un ad\u00e9nocarcinome r\u00e9nal m\u00e9tastatique;    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    en association avec le pembrolizumab pour le traitement du cancer de l\u2019endom\u00e8tre avanc\u00e9 chez les patientes adultes dont les tumeurs ne pr\u00e9sentent pas d\u2019instabilit\u00e9 microsatellitaire \u00e9lev\u00e9e (MSI-H) ni de d\u00e9ficience du syst\u00e8me de r\u00e9paration des m\u00e9sappariements (SRM), dont la maladie a \u00e9volu\u00e9 apr\u00e8s un traitement \u00e0 action g\u00e9n\u00e9rale \u00e0 base de platine et qui ne sont pas candidates \u00e0 une intervention chirurgicale ou \u00e0 une radioth\u00e9rapie curatives.    <\/li>\n\n<\/ul>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f279dcf193b60e355df99dd9cbefba61\"><\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a7361869bdebf28826c53a967353971f\"><strong><span style=\"text-decoration: underline\">Usage clinique<\/span>&nbsp;: <\/strong><\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--7bc34dc69b733d7767809de88ccbcaae\">L\u2019innocuit\u00e9 et l\u2019efficacit\u00e9 de LENVIMA\u00ae n\u2019ont pas \u00e9t\u00e9 \u00e9tablies chez les patients de moins de 18&nbsp;ans.<br><br>Le taux d\u2019abandon du traitement par LENVIMA\u00ae ou d\u2019effets ind\u00e9sirables de grade&nbsp;3 ou plus a \u00e9t\u00e9 plus \u00e9lev\u00e9 chez les patients \u00e2g\u00e9s de \u2265&nbsp;65&nbsp;ans que chez ceux qui \u00e9taient plus jeunes.<\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--29c7b05ff107449be5ba5e3d702ffd04\"><span style=\"text-decoration: underline\"> <strong>Mises en garde et pr\u00e9cautions les plus importantes<\/strong><\/span><strong> :<\/strong><br><br><strong>Hypertension et complications lui \u00e9tant associ\u00e9es, dont la dissection aortique mortelle &nbsp;<span lang=\"FR-CA\" style=\",sans-serif\"><\/span><br><\/strong><br><strong>Insuffisance cardiaque, parfois mortelle <span lang=\"FR-CA\" style=\",sans-serif;background:yellow\"><\/span><br><\/strong><br><strong>Thromboembolie art\u00e9rielle, parfois mortelle<\/strong><br><br><strong>Perforation gastro-intestinale et formation d\u2019une fistule gastro-intestinale&nbsp; <span lang=\"FR-CA\" style=\",sans-serif;color:blue;background:yellow\"><\/span><br><\/strong><br><strong>Fonctions h\u00e9patique, biliaire et pancr\u00e9atique&nbsp;:<\/strong> H\u00e9patotoxicit\u00e9\/insuffisance h\u00e9patique, parfois mortelles<br><br><strong>Fonction r\u00e9nale&nbsp;: <\/strong>Insuffisance r\u00e9nale et alt\u00e9ration de la fonction r\u00e9nale, parfois mortelle.<br><br><strong>Syst\u00e8me sanguin et lymphatique&nbsp;: <\/strong>H\u00e9morragie, parfois mortelle<br><br><strong>Syst\u00e8me nerveux&nbsp;: <\/strong>Syndrome d\u2019enc\u00e9phalopathie post\u00e9rieure r\u00e9versible (SEPR)<\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--28caa28a14b8e4cd1697bfb698c18365\"><strong><u>Autres mises en garde et pr\u00e9cautions pertinentes<\/u>&nbsp;:<\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--d35be11cc368ca0b1f59a76ae4e723d5 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"fr-CA\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Traitements anticanc\u00e9reux ant\u00e9rieurs    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Allongement de l\u2019intervalle\u00a0QT; corriger les anomalies \u00e9lectrolytiques chez tous les patients. \u00c9viter l\u2019utilisation des m\u00e9dicaments qui modifient les \u00e9lectrolytes    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Hypocalc\u00e9mie    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Alt\u00e9ration de la suppression de la thyr\u00e9ostimuline\/dysfonctionnement thyro\u00efdien    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Diarrh\u00e9e\u00a0: instaurer rapidement des mesures de prise en charge m\u00e9dicale    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Ost\u00e9on\u00e9crose de la m\u00e2choire (ONM)\u00a0: envisager un examen dentaire et une intervention pr\u00e9ventive avant de commencer le traitement par LENVIMA\u00ae. \u00c9viter le plus possible les interventions dentaires effractives. La prudence est de mise chez les patients recevant des agents associ\u00e9s \u00e0 une ONM, comme les bisphosphonates et le denosumab    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Complications li\u00e9es \u00e0 la cicatrisation des plaies    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Prot\u00e9inurie    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Fertilit\u00e9    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Les hommes et les femmes aptes \u00e0 procr\u00e9er doivent utiliser une m\u00e9thode de contraception    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Grossesse\u00a0: LENVIMA\u00ae doit \u00eatre utilis\u00e9 pendant la grossesse seulement en cas de n\u00e9cessit\u00e9 absolue et apr\u00e8s une \u00e9valuation minutieuse des besoins de la m\u00e8re et des risques pour le f\u0153tus    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Allaitement\u00a0: LENVIMA\u00ae ne doit pas \u00eatre utilis\u00e9 par les femmes qui allaitent    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    LENVIMA\u00ae n\u2019est pas recommand\u00e9 chez les patients atteints de n\u00e9phropathie terminale    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Surveillance et analyses de laboratoire    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Lorsque LENVIMA\u00ae est administr\u00e9 en association avec le pembrolizumab, consulter la monographie du pembrolizumab    <\/li>\n\n<\/ul>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f279dcf193b60e355df99dd9cbefba61\"><\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--36ae61139a28a8113a53471b4823484e\"><strong><span style=\"text-decoration: underline\">Pour de plus amples renseignements<\/span>&nbsp;:<span lang=\"FR-CA\" style=\",sans-serif\"><\/span><br><\/strong><br>Veuillez consulter la <a href=\"https:\/\/ca.eisai.com\/-\/media\/Files\/CanadaEisai\/LENVIMA-Product-Monograph-FR.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">monographie de LENVIMA\u00ae<\/a> pour obtenir des renseignements importants, sur les effets ind\u00e9sirables, les interactions m\u00e9dicamenteuses et la posologie qui n\u2019ont pas \u00e9t\u00e9 abord\u00e9s dans le pr\u00e9sent document. Vous pouvez aussi obtenir la monographie du produit en appelant Eisai&nbsp;Limit\u00e9e au <span class=\"no-text-breaking\">1&nbsp;877&nbsp;873-4724.<\/span><br><br>IMS&nbsp;=&nbsp;forte instabilit\u00e9 microsatellitaire; <span class=\"no-text-breaking\">LHc&nbsp;=&nbsp;lymphome<\/span> de Hodgkin classique; <span class=\"no-text-breaking\">LMPCB&nbsp;= lymphome<\/span> m\u00e9diastinal primitif \u00e0 cellules&nbsp;B; <span class=\"no-text-breaking\">SRM&nbsp;=&nbsp;syst\u00e8me<\/span> de r\u00e9paration des m\u00e9sappariements.&nbsp;&nbsp;&nbsp;<\/p>\n\n        <\/div>\n    <\/div>\n<\/div>\n\n\n\n<div class=\"mhh-sticky-footer-safety-content\">\n    <\/div>\n","protected":false},"template":"","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"0","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"promomats_ca_generated_at":0,"promomats_ca_screen_sizes":["Desktop","Mobile"],"footnotes":""},"mh-depends-on":[],"class_list":["post-81221","mhh-sticky-footer","type-mhh-sticky-footer","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Keytruda Lenvima Sticky - Merck Connect<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/keytruda-lenvima-sticky\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Keytruda Lenvima Sticky - Merck Connect\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/keytruda-lenvima-sticky\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck Connect\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-23T19:30:51+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/keytruda-lenvima-sticky\/\",\"url\":\"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/keytruda-lenvima-sticky\/\",\"name\":\"Keytruda Lenvima Sticky - Merck Connect\",\"isPartOf\":{\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/#website\"},\"datePublished\":\"2025-09-09T13:21:47+00:00\",\"dateModified\":\"2026-01-23T19:30:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/keytruda-lenvima-sticky\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/keytruda-lenvima-sticky\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/keytruda-lenvima-sticky\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.merckconnect.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Keytruda Lenvima Sticky\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/#website\",\"url\":\"https:\/\/www.merckconnect.ca\/fr\/\",\"name\":\"Merck Connect\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.merckconnect.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/#organization\",\"name\":\"Merck Connect\",\"url\":\"https:\/\/www.merckconnect.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.merckconnect.ca\/fr\/wp-content\/uploads\/sites\/8\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png\",\"contentUrl\":\"https:\/\/www.merckconnect.ca\/fr\/wp-content\/uploads\/sites\/8\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png\",\"width\":1284,\"height\":331,\"caption\":\"Merck Connect\"},\"image\":{\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Keytruda Lenvima Sticky - Merck Connect","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/keytruda-lenvima-sticky\/","og_locale":"fr_CA","og_type":"article","og_title":"Keytruda Lenvima Sticky - Merck Connect","og_url":"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/keytruda-lenvima-sticky\/","og_site_name":"Merck Connect","article_modified_time":"2026-01-23T19:30:51+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/keytruda-lenvima-sticky\/","url":"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/keytruda-lenvima-sticky\/","name":"Keytruda Lenvima Sticky - Merck Connect","isPartOf":{"@id":"https:\/\/www.merckconnect.ca\/fr\/#website"},"datePublished":"2025-09-09T13:21:47+00:00","dateModified":"2026-01-23T19:30:51+00:00","breadcrumb":{"@id":"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/keytruda-lenvima-sticky\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/keytruda-lenvima-sticky\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/keytruda-lenvima-sticky\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.merckconnect.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Keytruda Lenvima Sticky"}]},{"@type":"WebSite","@id":"https:\/\/www.merckconnect.ca\/fr\/#website","url":"https:\/\/www.merckconnect.ca\/fr\/","name":"Merck Connect","description":"","publisher":{"@id":"https:\/\/www.merckconnect.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckconnect.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.merckconnect.ca\/fr\/#organization","name":"Merck Connect","url":"https:\/\/www.merckconnect.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.merckconnect.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.merckconnect.ca\/fr\/wp-content\/uploads\/sites\/8\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png","contentUrl":"https:\/\/www.merckconnect.ca\/fr\/wp-content\/uploads\/sites\/8\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png","width":1284,"height":331,"caption":"Merck Connect"},"image":{"@id":"https:\/\/www.merckconnect.ca\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.merckconnect.ca\/fr\/wp-json\/wp\/v2\/mhh-sticky-footer\/81221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckconnect.ca\/fr\/wp-json\/wp\/v2\/mhh-sticky-footer"}],"about":[{"href":"https:\/\/www.merckconnect.ca\/fr\/wp-json\/wp\/v2\/types\/mhh-sticky-footer"}],"version-history":[{"count":6,"href":"https:\/\/www.merckconnect.ca\/fr\/wp-json\/wp\/v2\/mhh-sticky-footer\/81221\/revisions"}],"predecessor-version":[{"id":82349,"href":"https:\/\/www.merckconnect.ca\/fr\/wp-json\/wp\/v2\/mhh-sticky-footer\/81221\/revisions\/82349"}],"wp:attachment":[{"href":"https:\/\/www.merckconnect.ca\/fr\/wp-json\/wp\/v2\/media?parent=81221"}],"wp:term":[{"taxonomy":"mh-depends-on","embeddable":true,"href":"https:\/\/www.merckconnect.ca\/fr\/wp-json\/wp\/v2\/mh-depends-on?post=81221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}